Overview

HDAX Therapeutics is developing a targeted therapeutics platform for the safe and efficacious treatment of HDAC-driven pathologies such as neuropathies and cancers by rationally designing therapies to overcome common drug challenges including weak binding, off-target toxicities, and poor pharmacokinetic profiles.

Leadership
  • Nabanita Nawar, PhD

    Chief Executive Officer

  • Pimyupa Manaswiyoungkul, PhD

    Chief Operations Officer

  • Olasunkanmi Olaoye, PhD

    Vice President Drug Discovery

  • Elvin de Araujo, PhD

    Chief Innovation Officer

  • Patrick Gunning, PhD

    Scientific Advisor

See all alumni